The pharma industry claims lower prescription drug prices will mean less access to new medication for Canadians. It’s an old threat that pits profits against patients’ rights to affordable drugs.
Academic rigor, journalistic flair
Articles on Drug approval
Displaying all articles
The next step in HIV prevention — long-acting injectable pre-exposure prophylaxis (PrEP) — is not yet available in Canada, a year after its approval in the U.S.
Canada lags behind other developed countries in access to newer antimicrobials. Here’s why that matters, and what can be done about it.
When drugs are taken off the market because they are either unsafe or don’t work, do pharma companies admit that there are problems? Or do they deny the evidence?
FDA approval of aducanumab (Aduhelm) was contentious. Its submission to Health Canada for approval highlights concerns about evidence, independence and transparency in Canada’s drug approval process.
It usually takes 10 years for a new vaccine to complete clinical trials, but we’ve been promised a COVID-19 vaccine in 12 to 18 months. Even if such fast-tracked development is possible, is it wise?
Nexplanon, a long-acting reversible contraceptive that is implanted in the arm for up to three years, is a welcome addition to birth control options in Canada.
National drug regulators use evidence from clinical trials to decide whether new cancer drugs will be approved for use. But these studies are often flawed.
Health Canada proposes to increase fees to the pharmaceutical industry for prescription drug approval. This will compromise drug safety and is a risk to the health of the Canadian public.
Medical tourism is the practice of seeking medical care across international borders. Countries with established medical sectors like the US, Europe, India and Thailand have been traditional destinations…
In the last six months Colorado, Louisiana, Missouri, Michigan and, most recently, Arizona have passed “right to try” laws that allow terminally ill patients to access treatments that have only passed…
On November 4, the state of Arizona will decide whether to join Colorado, Missouri, Louisiana and Michigan in passing so-called right to try laws. If passed, the “Arizona Terminal Patients’ Right To Try…
Developing new drugs is hard and expensive. The lengthy process from initial discovery to the market is some times compared to the difficulty of putting a person on the moon. Despite accusations that the…
Between 2005 and 2011, nearly half of all new drug formulations in the US were approved without companies having to demonstrate a tangible benefit, such as relieving disease symptoms, extending life, or…
Top contributors
-
Professor Emeritus of Health Policy and Management, York University, Canada
-
Senior lecturer, University of South Australia
-
Ontario Research Chair in Bioethics and Public Policy, Queen's University, Ontario
-
Professor of Law and Public Health, The Ohio State University
-
Assistant Professor of Oncology at the School of Medicine, Johns Hopkins University
-
Professor, Health Sciences, Simon Fraser University
-
Professor, Department of Geography and Canada Research Chair in Health Service Geographies, Simon Fraser University
-
Associate professor, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
PhD, School of Nursing, Dalhousie University
-
Professor of Biocchemistry and Biomedical Sciences, McMaster University
-
Professor of Immunology and Associate Dean, Research and Graduate Studies, University of Guelph
-
Associate Professor of Viral Immunology, Department of Pathobiology, University of Guelph
-
Postdoctoral Associate, Rotman Institute of Philosophy, Western University
-
Associate Professor, Public Health & Social Policy; Special Advisor Health Research, Office of the Vice-President Research and Innovation, University of Victoria
-
Clinician-Scientist, St. Michael’s Hospital; Associate Professor, Faculty of Medicine, University of Toronto
